Positive effect in EAE and preclinical T1D (47), and IBD (77). Negative effect in human leishmaniasis (78). Inhibition of IGF-1 activity improved atherosclerosis in a pig model (79). This evidence concerns the gene IGF1 and inflammatory bowel disease.